Introduction
Platelet aggregometry requires the use of specialist skills and equipment and is, therefore, generally only performed in a dedicated laboratory. 1 As an alternative to aggregometry, it has been suggested that platelet granule release factors can be measured as markers of platelet activation. 1 P-selectin (PS) is a cell-surface adhesion molecule found in alpha and dense granules of platelets Background. P-selectin (PS) is a marker of platelet activation measured on the platelet surface as platelet PS (pPS) or in serum as soluble PS (sPS). Controversy remains over the exact relationship between sPS, pPS, and other markers such as spontaneous platelet aggregation (SPA). Objective. To investigate correlations between pPS, sPS, and SPA in patients with peripheral arterial disease. Methods. SPA, pPS, and sPS levels were measured in venous blood sampled from patients following intermittent claudication (n = 18) or an acute stroke (n = 18). Results. SPA and sPS correlated significantly in the claudicants (Pearson correlation coefficient, r = 0.661; P = .0020) and stroke patients (r = 0.514; P = .020). No significant correlation was identified between pPS and SPA, or sPS and pPS. Conclusions. The 2 methods of assessing PS are not comparable. Although pPS is accepted as a platelet activation marker, sPS may be a better indicator of aggregation represented by SPA.
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The aim of this study was to assess whether pPS correlated with sPS in patients with intermittent claudication or with an acute ischemic stroke. We also investigated the relationship between pPS or sPS and a conventional marker of platelet activationnamely, spontaneous platelet aggregation (SPA)-in these patients.
Materials and Methods

Patients
The markers of platelet activation, pPS and sPS, were assessed in 2 studies. Both studies involved patients with peripheral arterial disease (PAD) because this population is associated with platelet hyperactivity. 2 Study 1 was an observational study correlating platelet activation markers in patients post-acute-ischemic stroke. Study 2 assessed activation in claudicants after exercise. Both studies received local ethical approval and were performed according to the Declaration of Helsinki. Informed consent was obtained from all patients prior to their participation. Study 1: acute stroke patients. Inclusion criteria included patients admitted to the hospital acute stroke service with the diagnosis of an acute ischemic stroke, confirmed by CT scan. Exclusion criteria included anticoagulation, malignancy, renal failure, type 1 diabetes, current infection, platelet disorders, poor venous access, and treatment with steroids or thienopyridines. Prior to phlebotomy, all patients were given a loading dose of 300 mg of aspirin as per departmental protocol. Study 2: claudicants postexercise. The inclusion criteria were the following: patients previously started on aspirin 75 mg once daily, with proven lower-limb PAD (Duplex/angiogram and an ankle brachial pressure index < 0.9), without evidence of critical ischemia, and able to complete a standardized treadmill test. The exclusion criteria were the same as for study 1, with the addition of musculoskeletal or neurological conditions limiting compliance with the treadmill test. All patients performed 3 consecutive treadmill tests to maximal claudication distance to produce platelet activation (3.2 km/h at an incline of 10°). Blood was sampled after the third treadmill test.
Blood Collection
Venous blood was taken from the antecubital fossa without tourniquet pressure, using a 19G needle. The first 5 mL was discarded before collection into vacutainers containing 1/10 volume of 3.8% sodium citrate. For the measurement of sPS, plasma was isolated from blood by centrifuging (10 min at 1000 g) and stored at −80°C until assayed.
Flow Cytometry
Flow cytometry was used to evaluate pPS expression. It was performed using a whole-blood, 2-color staining technique. The system follows the principles outlined in the European Working Group on Clinical Cell Analysis' protocol for platelet analysis and is similar to the methods previously described. 3, 4 The assay focused on measuring pPS on populations of single platelets identified using light-scattering properties and a platelet-specific conjugated antibody (anti-CD61). PS was then measured in this singleton platelet population, which was excluded from other cells and platelet aggregates. This assay can only quantify PS on circulating platelets. There are no standardized methods to evaluate in vivo platelet adherence to areas of vascular damage. All antibodies were obtained from BD Biosciences (Oxford, UK). A peridinin chlorophyll protein-conjugated anti-CD61 antibody (PerCP-CD61) was used as a general platelet marker, and a phytocoerythrin (PE)-conjugated antibody to CD62P (PE-CD62P) was used to identify the surface expression of pPS. Control samples were run in parallel using isotypic PE-conjugated IgG 1 antibody. Saturating concentrations of fluorescent conjugated murine monoclonal antibodies were incubated with 5 μL of citrated whole blood for 20 minutes at room temperature. Following incubation, blood was fixed with 0.5% paraformaldehyde (Sigma, Poole, UK) and 0.1% azide (Sigma, Poole, UK) in phosphate-buffered saline solution. Samples were stored at 4°C in the dark until analysis within 4 hours, using a single FACScan flow cytometer (BD Biosciences, Oxford, UK). Light scatter and fluorescent characteristics were used to identify singleton platelet populations. Platelet events were triggered for cells expressing PerCP-CD61 and activation measured as the percentage of platelets expressing PE-CD62P. Polyfluorescent beads (Dakospheres; Dako, Ely, UK) were used to check calibration of the FACScan. Data were obtained with gain settings in the logarithmic mode, saved as list mode files, and analyzed using Winmidi 2.8 flow cytometry analysis software.
Soluble P-selectin
sPS was measured in stored plasma using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Abingdon, UK). This assay uses a quantitative sandwich immunoassay method and was fully automated (Best 2000, Biokit Eliza systems, UK).
Whole-Blood SPA
Platelet aggregation was measured by whole-blood free platelet counting as previously described. 5, 6 This technique makes use of the fall in singleton platelets as platelet aggregation proceeds. Analysis was begun within 5 minutes of phlebotomy using platelet counts, prestirring and poststirring, obtained with a Coulter ACT-8 counter (Beckman Coulter, High Wycombe, UK). Citrated anticoagulated blood (500 μL) was transferred to aggregation cuvettes (Chrono-Log, Havertown, USA), and a baseline platelet count was obtained. Aggregation was then facilitated by stirring blood at 1000 rpm at 37°C, and SPA was measured as the percentage reduction in platelet count after 3 minutes.
Statistical Analysis
Data were analyzed using Minitab (release 13.0). The Anderson-Darling test was used to confirm normal distribution. The Pearson correlation coefficient (r) was calculated. Results are expressed as means with standard deviation (SD). P values of less than .05 were considered significant. We could not do power calculations because of a lack of previous results comparing the variables we measured, in the patient population we studied.
Results
In total, we studied 18 claudicants and 18 stroke patients. The demographics of each population are summarized in Table 1 . The relationship between the 3 measures of platelet activation are summarized in Figures 1 to 6 . When SPA and pPS levels were compared, there was no significant correlation between SPA and pPS in either the stroke (r = 0.160, P = .524) or claudicant populations (r = 0.275, P = .270).
However, in both populations, a significant correlation between SPA and sPS was identified, with a strong correlation in the claudicants (r = 0.657, P = .003) and a moderate correlation in the stroke population (r = 0.540, P = .021). Surprisingly, there was no significant correlation observed between pPS levels and sPS in either population (stroke: r = 0.335, P = .174; claudicants: r = 0.210, P = .403).
Discussion
We found a significant correlation between SPA and sPS in patients with PAD. However, no correlation was identified between pPS and SPA or pPS and sPS. Other studies attempted to correlate sPS and pPS. McCabe et al failed to demonstrate a correlation between these 2 parameters following transient ischemic attacks or ischemic strokes, although they did not perform aggregometry. 7 Others compared pPS and sPS in patients with inflammatory bowel disease and identified elevated levels of pPS in the inflammatory bowel disease group (compared with healthy controls) but no difference in sPS, again without performing aggregometry. 8 Gurbel et al were also unable to correlate sPS and pPS in patients with chest pain. In this study, following successful thrombolysis, elevated sPS was noted, whereas pPS did not increase. 9 In another study, the authors were P-selectin and Spontaneous Platelet Aggregation / Cleanthis et al 229 able to correlate sPS and pPS in healthy controls but actually identified an inverse correlation in patients with atrial fibrillation. It was postulated that a lower pPS level may represent a conversion to sPS, subsequent to ongoing platelet activation in atrial fibrillation. 10 In patients with congestive heart failure, both sPS and pPS were shown to be significantly elevated, although no correlations between the 2 forms of PS were published. 11 Both pPS and sPS have been associated with atherosclerotic disorders. sPS was elevated in patients with either PAD or coronary heart disease (CHD), compared with healthy controls. [12] [13] [14] Interestingly, sPS changes following angiography and angioplasty may vary according to the pattern of disease. In CHD patients, elevated sPS levels were identified after angiography and angioplasty, whereas in PAD patients, sPS levels decreased after angiography and angioplasty. 15, 16 The majority of published work suggests a predictive role for sPS and subsequent vascular ischemic events. 17 Some debate still remains regarding the relationship between sPS and unstable CHD. 14, 18 In claudicants, elevated sPS levels have been associated with exercise and late restenosis following angioplasty. 19, 20 CHD has been strongly associated with pPS. [21] [22] [23] Flow cytometry has been used to identify elevated PS levels in populations with lowerlimb PAD and ischemic stroke. [24] [25] [26] [27] A recent study has shown elevated levels of both sPS and pPS in patients with lower-limb PAD. The same study also compared the expression of these markers in 2 different populations of lower-limb PAD: one with severe disease and the other with moderate disease. The expression of either sPS or pPS was not significantly different between these 2 populations. Interestingly, using multivariate analysis, sPS independently predicted disease severity. 28 SPA is the aggregation occurring (in the absence of an exogenous soluble agonist) as the result of shear stress imparted by stirring blood, which acts as a platelet agonist. The variation in cardiovascular risk factors between healthy individuals and PAD patients also alter platelet function. Furthermore, healthy age-matched controls may be an artificial comparison because only symptomatic atherosclerosis can be excluded. Previously published data have shown that SPA is enhanced in patients with PAD compared with matched controls and has also been linked with CHD, cerebrovascular disease, and idiopathic thrombocytopenia. 5, [29] [30] [31] [32] [33] The correlation between SPA and sPS seen in this study may be a result of both aggregation and degranulation. The latter can occur without full progression to aggregation, so the correlation may not be entirely explained by aggregation alone. Activation of the GPIIb/IIIa complex results in fibrinogen binding and can occur with lower agonist levels than those required to produce degranulation. 34 Stimulated platelets will not necessarily proceed to full irreversible aggregation. However, expression of pPS is an irreversible process, and so PS may be released from platelets at this stage. This is contrary to endothelial surface PS expression, which can be followed by internalization of membrane PS. 35 The origin of sPS has been questioned. There is evidence suggesting that platelets are a primary source, including correlations between platelet count and sPS, reduced levels with bone marrow aplasia, and elevated levels in platelet consumptive disorders. [36] [37] [38] [39] [40] [41] Further support for the platelet origin is provided by correlations with markers of platelet degranulation (eg, β-thromboglobulin). 42 Although an association with E-selectin has been seen, 43 other markers of endothelial activation, such as the von Willebrand factor, have not shown correlations with sPS. 13, 40, 42 In contrast to this, studies of hypertension-induced endothelial damage suggest that under pathological conditions, the endothelium may be an important source of sPS. 43 However, the evidence would appear to favor platelets as the primary source of sPS.
The clearance of activated platelets from the circulation is unlikely to be the same as for resting platelets. Although no correlation was seen between sPS and pPS, a complex relationship may exist where higher levels of sPS fail to correlate with pPS as a consequence of variations in clearance. The clearance of sPS and platelets expressing pPS requires further research. The differences may vary considerably depending on several factors: for example, the use of antiplatelet drugs, impaired renal function, and the state of leukocyte activation. The effect of pPS expression on platelet clearance has not been defined. If the half-life of pPS is affected by the degree of platelet activation, it is not surprising that flow cytometry results do not correlate with sPS. The relationship seen between sPS and SPA has been identified in 2 separate populations with PAD. Each population was studied by a different investigator, and hence, it is less likely to be an artifactual finding. pPS is accepted as a marker of platelet activation, but this study suggests that sPS may be a better marker of SPA. SPA is a measure of how sensitive the platelet is to activation by shear stress. Although it is measured ex vivo in a cuvette, it is done so in whole blood and hence represents the in vivo sensitivity of platelets. The shear stress is created ex vivo but represents a stimulus applied to the platelets within the blood. Further work is required to identify whether sPS is a marker of shear-induced aggregation and hence explain the correlation with SPA. Measurement of these markers in clinical studies is needed. To understand the relationship between these parameters, further work is required, such as measuring sPS and pPS before and after SPA in the same blood sample. Other techniques of shear-induced platelet aggregation could also be used to assess this relationship. The possibility that shear forces may facilitate the conversion of pPS to sPS would provide some explanation of the relationship seen in this study.
Although both pPS and aggregation have a role in assessing platelet activity, our findings suggest that sPS is a reliable measure of platelet hyperactivity that correlates well with platelet aggregometry. Quantification of sPS may be less susceptible than pPS to artifactual activation, and the assay can be performed using stored blood. Hence, it may be more suitable for clinical studies. This concept needs to be evaluated in clinical trials where clinically relevant end points are assessed following treatment with antiplatelet agents.
